U.S. markets open in 5 hours 6 minutes

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
60.05+1.20 (+2.04%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close58.85
Open58.72
Bid0.00 x 800
Ask0.00 x 800
Day's Range58.70 - 60.29
52 Week Range55.07 - 137.61
Volume430,408
Avg. Volume851,738
Market Cap3.218B
Beta (5Y Monthly)1.02
PE Ratio (TTM)8.44
EPS (TTM)7.12
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est91.14
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
106% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    U.S. House panels expand probe into Emergent's Baltimore COVID-19 vaccine plant

    Two U.S. House panels have expanded their probe into problems at Emergent BioSolutions Inc's Baltimore plant and have asked Johnson & Johnson and AstraZeneca for documents related to their selection of the contract manufacturer for their COVID-19 vaccines. Manufacturing of J&J's vaccine at Emergent's plant in Baltimore was halted by the U.S. Food and Drug Administration following an error in which ingredients from AstraZeneca's shot, also being produced at the plant at that time, contaminated a batch of the J&J vaccine.

  • Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders
    Newsfile

    Faruqi & Faruqi, LLP is Investigating Emergent BioSolutions (EBS) on Behalf of its Shareholders

    New York, New York--(Newsfile Corp. - June 23, 2021) - Faruqi & Faruqi, LLP, a leading minority and Woman-owned national securities law firm, is investigating potential misconduct at Emergent BioSolutions Inc. ("Emergent BioSolutions" or the "Company") (NYSE: EBS).The investigation focuses on whether the Company's Board of Directors and/or officers breached their fiduciary duties. Request more information now by clicking here: www.faruqilaw.com/EBS. There is no cost or obligation to you.Take Act

  • Promise Emerging for Emergent BioSolutions
    TipRanks

    Promise Emerging for Emergent BioSolutions

    Emergent BioSolutions (EBS) is a life sciences company with a focus on serving civilian and military clients by providing solutions for public health threats. The main value for EBS comes from its diversified product portfolio and pipeline, alongside its CDMO services that address public health threats. As a trusted partner to governments, NGOs, and major pharmaceutical and biotech innovators, it commands a leadership position in key public health threat markets. The company operates four busine